HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to tackle tough lymphoma cases
Disease control Recruiting nowThis study tests whether combining two drugs, loncastuximab tesirine and epcoritamab, can safely and effectively treat people with aggressive B-cell lymphoma that has come back or not responded to prior therapy. The trial will include 120 adults who have either not had CAR-T cell…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
CAR t therapy aims to snuff out hidden lymphoma cells
Disease control Recruiting nowThis study tests whether a personalized cell therapy called liso-cel can stop large B-cell lymphoma from returning in patients who still have traces of cancer DNA after initial treatment. About 50 adults who are in remission but test positive for lymphoma DNA will receive their o…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New strategy targets lingering lymphoma DNA in seniors
Disease control Recruiting nowThis study is for people aged 70 and older with a type of blood cancer called DLBCL. After initial chemotherapy, a blood test checks for leftover cancer DNA. If found, patients receive an extra targeted drug (mosunetuzumab) to try to clear it. The goal is to improve disease contr…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC